[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469537":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":31,"locations":37,"responsibleParty":164,"collaborators":166,"id":169,"slug":170,"hasResults":171,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":11,"eligibilityCriteria":175,"healthyVolunteers":171,"sex":176,"minAge":177,"maxAge":11,"enrollmentInfo":178,"targetDuration":11,"studyType":181,"phases":182,"briefSummary":185,"conditions":186,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},{"fullName":5,"class":6},"Qurient Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose escalation (Q901)","EXPERIMENTAL",null,[13],"Drug: Q901",{"label":15,"type":10,"description":11,"interventionNames":16},"Q901 Single-Agent Expansion Cohorts",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Q901 + KEYTRUDA® (pembrolizumab) Cohorts",[13,20],"Drug: KEYTRUDA® (pembrolizumab)",[22,27],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","Q901","The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter",[9,18,15],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"KEYTRUDA® (pembrolizumab)","KEYTRUDA® (pembrolizumab) will be administered Q6W",[18],[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Qurient Clinical Trial Information","CONTACT","+82-31-8060-1610","clinicaltrial_info@qurient.com",[38,55,67,78,90,101,113,125,136,146,157],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Mayo Clinic","RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-112.07404,33.44838,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},"See Central Contact",{"facility":56,"status":40,"city":57,"state":58,"zip":59,"country":44,"countryCode":45,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"University of Southern California","Los Angeles","California","90033",{"type":47,"coordinates":61},[62,63],-118.24368,34.05223,{"lat":63,"lon":62},[66],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":39,"status":40,"city":68,"state":69,"zip":70,"country":44,"countryCode":45,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Jacksonville","Florida","32224",{"type":47,"coordinates":72},[73,74],-81.65565,30.33218,{"lat":74,"lon":73},[77],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":79,"status":40,"city":80,"state":81,"zip":82,"country":44,"countryCode":45,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Northwestern University","Chicago","Illinois","60611",{"type":47,"coordinates":84},[85,86],-87.65005,41.85003,{"lat":86,"lon":85},[89],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":39,"status":40,"city":91,"state":92,"zip":93,"country":44,"countryCode":45,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Rochester","Minnesota","55905",{"type":47,"coordinates":95},[96,97],-92.4699,44.02163,{"lat":97,"lon":96},[100],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":102,"status":40,"city":103,"state":104,"zip":105,"country":44,"countryCode":45,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Atlantic Health System Hospital","Morristown","New Jersey","07960",{"type":47,"coordinates":107},[108,109],-74.48154,40.79677,{"lat":109,"lon":108},[112],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":114,"status":40,"city":115,"state":116,"zip":117,"country":44,"countryCode":45,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Mary Crowley Cancer Research","Dallas","Texas","75230",{"type":47,"coordinates":119},[120,121],-96.80667,32.78306,{"lat":121,"lon":120},[124],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":126,"status":40,"city":127,"state":11,"zip":11,"country":128,"countryCode":11,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"National Cancer Center","Goyang-si","South Korea",{"type":47,"coordinates":130},[131,132],126.835,37.65639,{"lat":132,"lon":131},[135],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":137,"status":40,"city":138,"state":11,"zip":11,"country":128,"countryCode":11,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"CHA University Bundang Medical Center","Seongnam-si",{"type":47,"coordinates":140},[141,142],127.13778,37.43861,{"lat":142,"lon":141},[145],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":147,"status":148,"city":149,"state":11,"zip":11,"country":128,"countryCode":11,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Asan Medical Center","NOT_YET_RECRUITING","Seoul",{"type":47,"coordinates":151},[152,153],126.9784,37.566,{"lat":153,"lon":152},[156],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":158,"status":148,"city":149,"state":11,"zip":11,"country":128,"countryCode":11,"cosmosGeoPoint":159,"geoPoint":161,"contacts":162},"Severance Hospital",{"type":47,"coordinates":160},[152,153],{"lat":153,"lon":152},[163],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":11},{"type":165,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[167],{"name":168,"class":6},"Merck Sharp & Dohme LLC","100469537","phase-1-highly-selective-cdk7-inhibitor-q901-in-selected-advanced-solid-tumors-100469537",false,"NCT05394103","Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","A Phase 1\u002F2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose","Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit\n* Measurable disease per RECIST v 1.1\n* ECOG performance status 0,1 or 2\n* Life expectancy of at least 3 months\n* Age ≥ 18 years\n* Signed, written IRB-approved informed consent form\n\nExclusion Criteria:\n\n* New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary\u002Fperipheral artery bypass graft, congestive heart failure within the past 6 months\n* Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of \\>470 msec (females) and \\>450 msec (males)\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n* Active, poorly controlled autoimmune or inflammatory diseases","ALL","18 Years",{"count":179,"type":180},130,"ESTIMATED","INTERVENTIONAL",[183,184],"PHASE1","PHASE2","Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab",[187,188],"Advanced Cancer","Metastatic Cancer","2025-08-13",{"date":191,"type":192},"2025-08-17","ACTUAL",{"date":194,"type":192},"2022-08-30",{"date":196,"type":180},"2026-08-30",{"name":5,"class":6},11]